argenx SE

NasdaqGS:ARGX Stock Report

Market Cap: US$49.7b

argenx Balance Sheet Health

Financial Health criteria checks 5/6

argenx has a total shareholder equity of $6.1B and total debt of $43.2M, which brings its debt-to-equity ratio to 0.7%. Its total assets and total liabilities are $7.2B and $1.1B respectively. argenx's EBIT is $796.6M making its interest coverage ratio -5.9. It has cash and short-term investments of $3.9B.

Key information

0.71%

Debt to equity ratio

US$43.15m

Debt

Interest coverage ratio-5.9x
CashUS$3.93b
EquityUS$6.10b
Total liabilitiesUS$1.08b
Total assetsUS$7.18b

Recent financial health updates

No updates

Recent updates

argenx: TED Phase 3 Failure, Vyvgart Growth, And Why I'm Still A Hold

Dec 17

Argenx: The Magic May Be Already Priced In

Mar 24

argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent

Feb 27

argenx: Lofty Valuation Diminishes Appeal Amid Autoimmune Expansion (Rating Downgrade)

Jan 23

Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat

Oct 31

argenx: Myositis Data Could Add Billions In Value

Sep 25

Argenx: Strong Setup For Outperformance In 2025

Jun 28

argenx: Innovation Over Losses In Autoimmune Arena

May 07

argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion

Feb 01

Argenx files for US approval of subcutaneous form of neuromuscular disorder drug efgartigimod

Sep 21

Argenx's neuromuscular disorder drug Vyvgart wins approval in EU

Aug 11

Argenx SE GAAP EPS of -$3.81 beats by $0.83, total operating income of $85.18M

Jul 28

argenx: A Very Good Start For Vyvgart

May 25

argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term Gain

May 18

argenx SE: Dutch Biotech Has Near Gain Ahead Says Hedging By Market-Makers

Mar 07

argenx: Vyvgart's Approval A Key Step For Continued Value Creation

Dec 22

argenx SE: Institutional Buying Turnaround In Dutch Biotech With Thin Audience Now Seen As Good Value By Market-Makers

Nov 30

argenx: R&D Day Goes Unnoticed

Aug 23

argenx: Next Phase Of Growth With Efgartigimod And ARGX-117

Jun 30

Financial Position Analysis

Short Term Liabilities: ARGX's short term assets ($5.8B) exceed its short term liabilities ($1.0B).

Long Term Liabilities: ARGX's short term assets ($5.8B) exceed its long term liabilities ($37.9M).


Debt to Equity History and Analysis

Debt Level: ARGX has more cash than its total debt.

Reducing Debt: ARGX's debt to equity ratio has increased from 0.4% to 0.7% over the past 5 years.

Debt Coverage: ARGX's debt is well covered by operating cash flow (935.7%).

Interest Coverage: ARGX earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/08 14:08
End of Day Share Price 2026/01/08 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

argenx SE is covered by 59 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Joel BeattyBaird
null nullBaird